甲基胺使用障碍患者周围血液中的α-synuclein增加
Mi Ran Choi1,2, Younghoon Chon3, Joongbum Cho4
1Laboratory Animal Research Center, Ajou University School of Medicine, Suwon, Republic of Korea.
Psychiatry investigation
|July 9, 2025
概括
血液中α-synuclein (α-Syn) 的升高可能表明甲基胺 (MA) 滥用的神经毒性. 这一发现表明α-Syn是MA诱导的神经退行性疾病的潜在生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 生物标志物发现发现
背景情况:
- 慢性甲基胺 (MA) 滥用导致神经毒性,破坏神经可塑性并加速神经退行.
- 确定可靠的生物标志物对于评估MA诱导的神经毒性和相关疾病至关重要.
研究的目的:
- 为了研究患有MA使用障碍的个体血液中的α-synuclein (α-Syn),脑衍生神经营养因子 (BDNF) 和神经元特异性酶 (NSE) 的表达水平.
- 确定这些蛋白质作为MA诱导神经毒性的生物标志物的潜力.
主要方法:
- 从30名患有MA使用障碍的患者和30名健康对照人群收集了血液样本.
- 多重测试工具被用于量化α-Syn,BDNF和NSE的表达水平.
主要成果:
- 与对照组相比,MA组的α-synuclein (α-Syn) 水平显著增加 (p=0.0473).
- 大脑衍生神经营养因子 (BDNF) 呈现出随着MA使用时间的持续增加的趋势 (p=0.082).
- 在两组之间观察到抑郁和焦虑得分的显著差异.
结论:
- 在MA使用者的血液中α-Syn的增加表明其作为MA诱导神经毒性的生物标志物的潜在作用.
- 这一发现意味着α-Syn的升高可能会穿过血脑屏障,反映出MA暴露导致的大脑变化.
- α-Syn需要进一步研究作为与MA滥用有关的神经退行性疾病的诊断标志物.
相关概念视频
Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...


